Furthermore, our in vitro studies also verified that depletion of SRC-3 either by RNA interference (RNAi) or small-molecule inhibitors sensitized the anti-MM efficacy of BTZ. This evidence concerns the gene NCOA3 and Miyoshi myopathy.